Sentences with phrase «hiv vaccine researchers»

Not exact matches

Researchers at Oregon Health & Science University are currently looking for volunteers that can be tested during an upcoming clinical trial for a vaccine that may cure HIV, the virus that causes AIDS.

To fend off HIV, researchers introduced one vaccine (ALVAC) to induce a T cell response — thereby alerting the immune system — and another (AIDSVAX) later to spur an antibody response.

Researchers for the past decade have focused on the T cell approach, based on studies showing that monkeys receiving such vaccines against simian immunodeficiency virus, related to HIV, lived longer or had lower viral levels than usual.

In collaboration with many researchers (graduate students, postdocs, and faculty elsewhere), we have examined the role of cross-immunity on the evolution and dynamics of influenza; the impact of behavioral changes, long periods of infectiousness, variable infectivity, co-infections, prostitution, social networks, and vaccine efficacy on HIV dynamics; the role of exogenous re-infection, variable progression rates, vaccination, public transportation, close and casual contacts on tuberculosis dynamics and control; the impact of life - history vector dynamics on dengue epidemics; and on the identification of time - response scales for epidemics of foot and mouth disease.

Researchers hope that the insights they are gleaning from the structure will open new doors to drug and vaccine intervention against HIV.

Researchers from the University of Zurich and University Hospital Zurich now reveal which factors are responsible for the human body forming such broadly neutralizing HIV antibodies, thereby opening new avenues for the development of an HIV vaccine.

At the start, researchers pinned their hopes on vaccines designed to trigger production of antibodies against HIV's surface protein.

Vaccine researchers typically start with antigens — in this case, pieces of HIV — and then evaluate the antibodies they elicit.

La Jolla Institute scientist Shane Crotty, Ph.D., a respected vaccine researcher and member of one of the nation's top AIDS vaccine consortiums, showed that certain helper T cells are important for triggering a strong antibody response against HIV, the virus that causes AIDS.

In an early - morning announcement today, researchers reported that an experimental HIV (human immunodeficiency virus) vaccine effectively reduced the number of people who contracted the virus by nearly a third.

A 2007 clinical trial of a vaccine made by Merck was stopped when researchers found that, in fact, more people who received the active vaccine (49) than the placebo (33) had contracted HIV.

In Britain, in 1991, researchers led by Jim Stott at the National Institute of Biological Standards and Control in north London, stunned their colleagues by announcing that they had apparently protected monkeys from infection with the monkey virus SIV — the simian equivalent of HIV — with a vaccine based simply on human T cells.

To fend off HIV, researchers introduced one vaccine (ALVAC - HIV) to induce a T cell response — thereby alerting the immune system — and another (AIDSVAX B / E) later to spur an antibody response.

The next step is a bigger trial where the researchers will combine romidepsin activation of hidden HIV with a vaccine (vacc - 4x) to strengthen the ability of killer T - cells to fight hiv virHIV with a vaccine (vacc - 4x) to strengthen the ability of killer T - cells to fight hiv virhiv virus.

An exception to this trend is Dong Pyou Han, a former Iowa State University (ISU) biomedical researcher who last week was sentenced to prison for 57 months — almost 5 years — for falsifying results in HIV vaccine studies he participated in while working under lab head Michael Cho, The Guardian reports.

The researchers are planning to test this method to deliver HIV vaccines in nonhuman primates, and they are also working on further developing cancer vaccines, including one for lung cancer.

The study, published Aug. 13, 2014, in the journal Cell Host & Microbe, builds on previous work from researchers at the Duke Human Vaccine Institute that outlined a perplexing quality about HIV: The antibodies that originally arise to fight the virus are ineffective.

By integrating the gp41 protein into the vaccine, researchers try to trigger the production of antibodies that would block the entrance of HIV into human cells.

Researchers led by a team at Duke University identified these immunologic variations by studying blood samples collected from people living with HIV by the NIAID - supported Center for HIV / AIDS Vaccine Immunology (CHAVI).

LONDON (Reuters)-- Researchers announced the launch of two big studies in Africa on Thursday to test a new HIV vaccine and a long - acting injectable drug, fuelling hopes for better ways to protect against the virus that causes AIDS.

Of more than 50 therapeutic vaccine trials so far, this is the first one that has bolstered the immune system in a «meaningful» way, says Steven Deeks, an HIV / AIDS clinician and researcher at the University of California, San Francisco, who is «cautiously optimistic» that the data will inspire others to study the approach.

HIV is finally revealing its weak spots to researchers, bringing an effective vaccine against AIDS closer to reality.

That's the question posed by researchers in the journal BMC Immunology, who think that the vaccine might have offered partial protection against HIV.

This is why it is so difficult for humans to mount an effective immune response and why it is challenging for researchers to develop vaccines targeting the HIV envelope proteins,» Dr. Blanchard says.

The researchers administered a potential vaccine consisting of two components to twelve rhesus monkeys that served as an animal model for the human HIV infection.

For 30 years, researchers have struggled to determine which immune responses best foil HIV, information that has guided the design of AIDS vaccines and other prevention approaches.

For decades, researchers have been trying — unsuccessfully — to develop a vaccine that spurs the body to attack HIV.

But as researchers turn to diseases that are more difficult to protect against, such as malaria or HIV, they are setting their sights lower, aiming for vaccines that prevent severe disease but not infection.

Although no vaccine against HIV exists, advances in prevention and treatment have led to a growing conviction among researchers, public health officials, and politicians that the HIV / AIDS epidemic can be brought to a halt with existing tools.

Early tests of a gp120 vaccine looked promising, but optimism faded by the early 1990s as researchers learned the vaccine only worked against strains of HIV that had adapted to conditions in the laboratory.

Researchers at the University of Maryland and Duke University have designed a novel protein - sugar vaccine candidate that, in an animal model, stimulated an immune response against sugars that form a protective shield around HIV.

Next, the researchers injected the protein - sugar vaccine candidate into rabbits and found that the rabbits» immune systems produced antibodies that physically bound to gp120 found in four dominant strains of HIV in circulation today.

Researchers have tried to create an HIV vaccine targeting gp120, but had little success for two reasons.

The researchers» next steps will be to conduct longer - term studies in combination with other vaccine candidates, hone in on what areas of gp120 the antibodies are binding to and determine how they can increase the antibodies» effectiveness at neutralizing HIV.

WITHIN a few weeks, researchers in Bangkok will start injecting people with a genetically engineered vaccine against HIV.

The row over the Thai trials has been fuelled by an explosive mix of factors, including the pace at which the HIV epidemic is growing in Asia, the future of the vaccines industry, and domestic tensions in the US between AIDS researchers, activists and politicians.

AIDS researcher Jay Levy at the University of California at San Francisco finds the results encouraging, but notes that the vaccines seemed to have no effect on the amount of virus in the bloodstream of people who contracted HIV during the study.

Speakers include Wistar scientists and renowned guest researchers who discuss topics such as cancer, aging, vaccines, immune disorders and allergies, HIV, and infectious diseases, all in an approachable way for a non-scientific audience.

Since coming to Fred Hutch, he has been working with Dr. Leo Stamatatos and other top researchers on HIV, but as his small, four - person lab grows, he wants to expand to include other infections for which a vaccine doesn't exist.

Researchers from the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research (WRAIR) have found that an experimental heroin vaccine induced antibodies that prevented the drug from crossing the blood - brain barrier in mice and rats.

In the new issue of IAVI Report we wrote about how researchers at the AIDS Vaccine 2010 conference in Atlanta discussed the limited window of opportunity for conducting clinical trials to test partially effective HIV prevention strategies, including HIV vaccine candidates and oral or topical antiretroviral pre-exposure prophylaxis (PrEP), in combiVaccine 2010 conference in Atlanta discussed the limited window of opportunity for conducting clinical trials to test partially effective HIV prevention strategies, including HIV vaccine candidates and oral or topical antiretroviral pre-exposure prophylaxis (PrEP), in combivaccine candidates and oral or topical antiretroviral pre-exposure prophylaxis (PrEP), in combination.

Researchers have long sought to develop an effective HIV vaccine.

These results may provide new ways for vaccine researchers to target HIV and may influence the design of future HIV vaccines.

After comparing the genetic strains of HIV in vaccine and placebo recipients, researchers found that cellular immune responses generated by the vaccine may have impacted the HIV - 1 strains that established infections (breakthrough viruses).

The trials would be for proof of concept, to show whether researchers can, for the first time in humans, stimulate the right B cells to start the process of making broadly neutralizing antibodies, long considered the «holy grail» of HIV vaccine research because they defend against infection by a broad spectrum of HIV strains.

Nearly 35 years after HIV, the virus that causes AIDS, was discovered, researchers at UNLV continue to forge ahead in the quest for prevention, education and a possible vaccine or cure.

AIDS vaccine researchers say they have some new clues to help focus their search for a safe and effective vaccine against HIV.

2012 — MHRP Researchers awarded $ 5 million grant to fund research into a novel heroin / HIV vaccine — The innovative dual - vaccine model would concurrently address the entwined epidemics of heron abuse and HIV and could provide considerable public health benefits.

Critically, such trials direct researchers towards protective immune responses we will need to generate with HIV vaccines that will help the body protect itself from this destructive, complicated and deadly disease.

Immune responses of patients could point way forward for future vaccines.In the latest study, researchers involved with the trial at Mahidol University in Bangkok and the U.S. Military HIV Research Program in Washington DC assembled a team to scour the blood of trial participants for immune indicators that differed between 41 people who received the vaccine and contracted HIV and 205 participants who did not become infected.